DSM Pharmaceutical Products has signed a three-year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, for the production of sterile products, including eribulin mesylate and other developmental drugs. DSM will supply eribulin mesylate for the U.S. market with commercial production expected to begin in early 2013. DSM will manufacture the product at its finished dosage facility in Greenville, NC. Financial details were not disclosed.
Laura Parks, president of DSM Pharmaceuticals, Inc., the finished dosage business of DSM, said, "It has been an honor to work with Eisai through the launch into commercial supply of eribulin mesylate and to continue to support the development of other products. Combining the expertise of Eisai in developing innovative medicines with DSM's strength in GMP, and supply chain management will provide critical high quality treatments for patients."
"Eisai appreciates the focus and effort the DSM Pharmaceuticals team in Greenville has provided in support of our commercial and developmental products. We are particularly pleased to have received FDA approval to manufacture eribulin mesylate at DSM for the commercial U.S. market. This alternate site of manufacturing strengthens the supply reliability of this important product for our patients," said Shawn Gallagher, president of partnership management CFU, Eisai Inc.